Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil
Αποθηκεύτηκε σε:
| Κύριος συγγραφέας: | |
|---|---|
| Ημερομηνία έκδοσης: | 2004 |
| Άλλοι συγγραφείς: | , , , , |
| Μορφή: | Article |
| Γλώσσα: | eng |
| Πηγή: | Repositório Institucional da UnB |
| Download full: | http://repositorio.unb.br/handle/10482/26148 https://dx.doi.org/10.1590/S0074-02762004000800016 |
Περίληψη: | In the context of universal access to antiretroviral therapy, the surveillance of human immunodeficiency virus type 1 (HIV-1) genetic diversity and resistance becomes pivotal. In this work our purpose was to describe the genetic variability; prevalence of drug-resistance mutations; and genotypic resistance profiles in HIV-1 infected individuals under antiretroviral treatment, from the Federal District, Brasília, Central Brazil. The entire viral protease and codons 19 to 234 of the reverse transcriptase gene from 45 HIV-1 isolates were amplified and sequenced for subtyping and genotyping. By phylogenetic analysis, 96% of the samples clustered with subtype B and the remaining 4% with HIV-1 subtype F sequences. One major protease inhibitor resistance-associated mutation, I50V, was detected in 38% of the samples. Minor mutations were also found at the protease gene: L10I/V (7%), K20M (2%), M36I (11%), L63P (20%), A71T (2%), and V77I (7%). Many mutations associated with reduced susceptibility to nucleoside or non-nucleoside reverse transcriptase inhibitors were detected: M41L (11%), E44D (4%), D67N (11%), T69D (2%), K70R (11%), L74V (2%), L100I (4%), K103N (18%), V118I (9%), Y181C (11%), M184V (18%), G190A (4%), T215Y (4%), and K219E (4%). This study has shown that 84% of the studied population from the Federal District, showing evidences of therapy failure, presented viral genomic mutations associated with drug resistance. The main antiretrovirals to which this population showed resistance were the PI amprenavir (38%), the NNRTIs delavirdine, nevirapine (31%), and efavirenz (24%), and the NRTIs lamivudine (18%), abacavir, and zidovudine (13%). |
Παρόμοια τεκμήρια: Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil
- Análise do perfil de resistência do vírus da imunodeficiência humana tipo 1 (HIV-1) aos inibidores da transcriptase reversa não análogos de nucleosídeos (ITRNN) em Goiás
- Planejamento e síntese de novos candidatos a protótipos de fármacos anti-HIV, desenhados a partir da delavirdina, um inibidor não nucleosídico da transcriptase reversa
- HIV-1 subtypes and mutations associated to antiretroviral drug resistance in human isolates from Central Brazil
- Avaliação clínico-epidemiológica dos pacientes com falha virológica e resistência genotípica do HIV-1 aos antirretrovirais no período de março de 2012 a março de 2017 no Distrito Federal
- Predictors of virologic failure in HIV/AIDS patients treated with highly active antiretroviral therapy in Brasília, Brazil during 2002–2008
- Adherence to antiretroviral therapy and viral suppression : analysis of three periods between 2011 and 2017 at an HIV-AIDS center, Brazil